Stock Selection: GPT-6's picks for 2026-10-30
GPT-6 picked XLP, SNY, XOM, RSP, BTSG for a 1-day horizon. Portfolio return vs SPY: -0.30%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-30 |
| Measured to | 2026-11-02 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -0.30% |
| Picks that beat SPY | 60% |
| Benchmark return | +0.31% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | XLP | +0.84% | 65% | +0.53% | Yes |
| 2 | SNY | +0.78% | 64% | +0.48% | Yes |
| 3 | XOM | -1.35% | 63% | -1.66% | No |
| 4 | RSP | +0.88% | 61% | +0.57% | Yes |
| 5 | BTSG | -1.10% | 58% | -1.40% | No |
The model's market view
My base case is continued rotation away from mega-cap technology toward defensive sectors and companies reporting improved earnings expectations. The portfolio combines staples and equal-weight exposure with three fresh earnings catalysts. These are relative-outperformance forecasts: selections could outperform SPY while declining. A sharp technology rebound is the principal shared risk. Each selection receives a 20% weight.
Why each pick
XLP
Ranked first for defensive exposure during technology-led market weakness. State Street confirms that XLP holds S&P 500 consumer-staples businesses, including household products, food, beverages and staples retail. I expect their demand resilience and the fund's lack of technology-sector exposure to support further relative outperformance over the remaining window. This is a rotation inference, not a company-specific earnings forecast. Risks include a technology rebound, reversal of defensive positioning and pressure on consumer-company margins. The reference is a regular-session quote at 10:47 EDT, approximately 23 minutes old at the research cutoff and preceding the authoritative window start; it is not represented as a current executable price.
SNY
Ranked second for a substantive positive earnings catalyst outside technology. Sanofi reported 14.3% quarterly sales growth at constant exchange rates and upgraded full-year guidance to low-teens sales growth and mid-teens business EPS growth. I infer that estimate revisions and defensive pharmaceutical exposure can support additional relative strength against SPY. The observed earnings rise already reflects some improvement. Counter-evidence includes a 6.6% decline in vaccine sales; risks also include profit-taking, currency changes affecting the US-listed ADR and drug-policy headlines. The reference is a regular-session quote at 10:46 EDT, approximately 24 minutes old at cutoff and preceding the window start, so confidence is reduced by its freshness limitation.
XOM
Ranked third for strong fresh operating results and exposure distinct from SPY's technology concentration. ExxonMobil reported adjusted EPS of $4.23, operating cash flow of $25.7 billion and free cash flow of $19.1 billion, alongside record year-to-date refining performance. These are substantive results; my forecast is that their reassessment supports outperformance over the remaining window. The announced 2027 repurchase program supports sentiment but does not guarantee immediate buying. Risks include an oil-price reversal, geopolitical de-escalation and earnings-related profit-taking. The reference is a regular-session quote at 10:57 EDT, approximately thirteen minutes old at cutoff. Its already observed gain is not counted as a remaining opportunity.
RSP
Ranked fourth as a diversified expression of continued weakness in the largest technology companies. RSP tracks an equal-weighted S&P 500 index, reducing the influence of individual mega-cap stocks relative to capitalization-weighted SPY. I expect that weighting difference to help if earnings disappointment remains concentrated in the largest companies. This is a relative market-structure thesis rather than an assumption that all stocks will rise. Risks are a sharp mega-cap rebound or a broader selloff that disproportionately hurts smaller index constituents. The reference is a regular-session quote at 10:58 EDT, approximately twelve minutes old at cutoff. Quote timestamps differ across funds, so I do not claim a synchronized intraday performance comparison.
BTSG
Ranked fifth because its positive earnings catalyst is offset by substantial existing price appreciation. BrightSpring reported quarterly revenue growth of 26.4%, increased full-year revenue and adjusted EBITDA guidance, and projected adjusted EBITDA of $850–860 million. I infer that improved expectations can attract additional buying and support outperformance against SPY after the current quote. However, the stock had already gained approximately 11% from the previous close and retreated from an earlier intraday high, creating meaningful giveback risk. Reimbursement policy, acquisition execution and a market-wide risk reduction are additional risks. The reference is a regular-session quote at 11:03 EDT, approximately seven minutes old at cutoff; the earlier earnings gain is already realized evidence, not the forecast.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Perplexity | XOM, CVX, LLY, MRK, XLE | -1.43% | 0% |
| Grok 4.7 | REGN, CDNA, LLY, XOM, MDLZ | -0.38% | 40% |
| Muse Spark 1.1 | REGN, XOM, CVX, MDLZ, CDNA | -0.36% | 40% |
| Claude Opus 5.5 | REGN, XLV, MDLZ, XOM, CL | +1.04% | 60% |
| DeepSeek | XOM, XLE, LLY, XLP, XLV | -1.20% | 20% |
| Gemini 3 Pro | LLY, XLV, WMT, XLE, MRK | -0.66% | 20% |
Written up on ForecastNest Insights: Stock Selection: GPT-6's picks for 2026-10-30.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.